Στις αρχές της δεκαετίας του 80 μια νέα εποχή ξεκινά για την Μαστογραφία και τον καρκίνο του Μαστού, με τη χρήση της τεχνικής "χαμηλής δόσης Μαστογραφίας", τη σωστή ενημέρωση των γυναικών για την πρόληψη του καρκίνου του μαστού και την εφαρμογή του πληθυσμιακού ελέγχου σε ασυμπτωματικές γυναίκες, με συνέπεια να αυξήσουν τον αριθμό των μη-ψηλαφητών και μη ψηλαφητών καρκίνων μαστού που διαγιγνώσκονται σε πρώιμα στάδια (0, Ι, ΙΙ, ΙΙΙΑ κλπ) με καλλίτερη πρόγνωση και θεραπεία. Προηγούμενες κλινικές μελέτες προσπάθησαν να συσχετίσουν τα ακτινολογικά με τα ιστολογικά χαρακτηριστικά του καρκίνου του μαστού αλλά δεν κατάφεραν να αναδείξουν σημαντικές διαφορές όσον αφορά τα ιστολογικά και βιολογικά χαρακτηριστικά μεταξύ των συμπωματικών και των μαστογραφικά εντοπιζόμενων μη ψηλαφητών καρκινωμάτων του μαστού . Επιπλέον, αρκετοί ερευνητές φαίνεται να καταλήγουν στο συμπέρασμα ότι τα καλά προγνωστικά χαρακτηριστικά των καρκινωμάτων του μαστού που αναδεικνύονται με την προληπτική μαστογραφία σχετίζονται άμεσα ή έμμεσα με την επίδραση βιολογικών παραγόντων. Σκοπός της παρούσας μελέτης είναι η ανάδειξη των δεικτών που σχετίζονται με την μαστογραφική απεικόνιση της κακοήθων ογκόμορφων αλλοιώσεων ψηλαφητών και μη και της επιθετικότητας της νόσου. Μελετήθηκαν συνολικά πεντακόσιες εβδομήντα τέσσερεις ογκόμορφες αλλοιώσεις ψηλαφητές ή μη του μαστού σε πεντακόσιες εβδομήντα ασθενείς που εντοπίστηκαν κατά τη διάρκεια του μαστογραφικού ελέγχου στο εργαστήριο μας κατά την περίοδο 1994- 2004. Όλοι οι ασθενείς υποβλήθηκαν σε βιοψία δια λεπτής βελόνης (FNA) ή κατευθυνόμενη από με μαστογραφία χειρουργική βιοψία. Η ιστολογική εξέταση ανέδειξε 410/574 (71,4%) κακοήθεις ογκόμορφες αλλοιώσεις και 164/574 (28,5%) καλοήθεις. Ανοσοϊστοχημεία πραγματοποιήθηκε σε τομές παραφίνης σε 390 από τις 410 κακοήθεις αλλοιώσεις χρησιμοποιώντας μία ποικιλία μονοκλωνικών και πολυκλωνικών αντισωμάτων ενάντια στις εξής πρωτεϊνες: ER, PR, p53, HER-2,Ki 67 και KATH D. Οι κακοήθεις ογκόμορφες αλλοιώσεις ταξινομήθηκα από την Μαστογραφική τους απεικόνιση (σύμφωνα Breast Imaging Reporting and Dada System BI RADS) σε τρείς κατηγορίες : στην κατηγορία Β (οι αστεροειδείς κακοήθεις ογκόμορφες αλλοιώσεις) ήταν το (44,8%), στην κατηγορία Α (οι άτονες με ασαφή ή εν μέρει ασαφή όρια) το 36% και στην κατηγορία Γ (σκιάσεις και αποτιτανώσεις) που ήταν 18,2% όλων των κακοήθων ογκόμορφων αλλοιώσεων. Η ανάλυση των αποτελεσμάτων μεταξύ της μαστογραφικής απεικόνισης των κακοήθων ογκόμορφων αλλοιώσεων και των ιστολογικών και βιολογικών χαρακτηριστικών των ανέδειξε : Σημαντική συσχέτιση της μαστογραφικής απεικόνισης με το μέγεθος των ογκόμορφων αλλοιώσεων (p=0.01<0.05). Σημαντική συσχέτιση με το βαθμό διαφοροποιήσεως της κακοήθειας (p=0.005<0.05). Σημαντική συσχέτιση με την έκφραση των πρωτεϊνών p53 (p=0.015) και Ki -67( p=0.02). Δεν παρατηρήθηκε σημαντική συσχέτιση της απεικόνισης των ογκόμορφων αλλοιώσεων με την ηλικία των ασθενών (p=0.08>0.05), με την ανίχνευση πυρηνικής θετικότητας για τους οιστρογονικούς (ER) και τους προγεστερονικούς(PR) υποδοχείς (p =0.4>0.05) καθώς και με τις πρωτεΐνες HER-2. και KATH D. Επίσης παρατηρήθηκε οριακή συσχέτιση στην απεικόνιση των κακοήθων ογκόμορφων αλλοιώσεων και των λεμφαδένων. Συμπερασματικά βρήκαμε ότι η κατηγορία Β με τις αστεροειδείς ογκόμορφες αλλοιώσεις είχε ευνοϊκότερη επίδραση από τ η κατηγορία Α με τις άτονες με ασαφή ή εν μέρει ασαφή όρια και με τις ογκομορφές αλλοιώσεις και αποτιτανώσεις (κατηγορία Γ). Οι άτονες με ασαφή ή με εν μέρει ασαφή όρια κακοήθεις ογκόμορφες αλλοιώσεις(κατηγορία Α) σχετίζονται με χαμηλής διαφοροποίηση κακοήθεια (grade 3) με υπερέκφραση του p53 και Ki -67 και με αρνητικούς υποδοχείς (PR και ER). Οι όγκοι αυτοί είναι μεγάλοι όγκοι με ίδια πολλές φορές μαστογραφική απεικόνιση με εκείνη των καλοηθών ογκόμορφων αλλοιώσεων. / At the beginning of 80 a new era for the Mammography and the breast cancer started with the use of the technique "low dose Mammography", with the correct information of women for the prevention of the breast cancer and the application of mass screening in asymptomatic women, with the result to increase the number of palpable and no- palpable breast cancers diagnosed in early stages (0,I,II,IIIA etr) with better prognosis and therapy. Previous clinical studies have attempted to correlate the radiological with the histological characteristics of breast cancer but did not succeed to show significant differences as for us the histological and biological characteristics among the symptomatic and the mammographically localized non- palpable breast cancers. Furthermore, many investigators see to conclude that the best prognostic characteristics of breast cancers that are identified with the preventive mammography are directly or indirectly related by the effect of biological factors. The aim of the present study is to mark out indicators that are related with the mammographic appearance of malignant palpable and no- palpable lesions and the aggressiveness of disease. In total five hundred seventy four palpable and no- palpable breast lesions have been studied in five hundred seventy patients that were localized during the mammographic screening in our department, between 1994 to 2004. All the patients were subjered to line needle biopsy (FNA) or mammographically guided open surgical biopsy. Histological examination showed 410/574 (71.4%) malignant lesions and 164/574 (28.5%) benign lesions. Immunohistochemistry was performed in paraffin sections in 390 of 410 malignant lesions using a variety of monoclonal and polyclonal antibodies against the following proteins ER,PR, P53, HER-2, Ki67and KATH D. The malignant lesions were classified from their mammographic appearance (according to Breast Imaging Reporting and Dada System BI RADS) in three categories: category A (lesions with poorly defined or partially poorly defined margins)were 36%, category B (speculated malignant lesions) were 44.8% and category C (lesions wih calcifications) were 18.2% of all malignant lesions. The analysis of our results between the mammographic appearance of the malignant lesions and their histological and biological characteristic showed the following: 1) Significant correlation existed between the mammographic appearance and the size of the lesions (p=0.01<0.05). 2) Significant correlation existed with the degree of differentiaton of malignancy (p=0.005<0.05). 3) Significant correlation existed with over expression of proteins P53 (p=0.015). and Ki- 67 (p=0.02). No significant correlation was observed between the appearance of lesins with the age of the patients (p=0.08>0.05), with the detection of nuclear positivity of the estrogens (ER) and progesterone (PR) receptors (p=0.4>0.05) and also with the proteins HER-2 and KATH D. Furthermore a bode line correlation was observed between the appearance of the malignant lesions and lymph notes. In summary, it was found that the category B patients with the speculated lesions had a more favorable effect than category A with the poorly defined or partially poorly defined limits, and the category C lesions with calcifications. The poorly defined or partially poorly defined limits malignant lesions (category A) are related with low grade malignancy (grade 3, with over expression of P53 and Ki-67 and with negative receptors (PR and ER). These are large size lesions and are difficulty diagnosed from benign lesions.

H θεραπεία της χρόνιας ηπατίτιδας C παραμένει πρόκληση ,ιδιαίτερα για κάποιους ασθενείς ,μια και ποικίλοι παράγοντες που αφορούν τόσο τον ιό όσο και τον ξενιστή σχετίζονται με χαμηλότερη ιολογική απάντηση στη θεραπεία .Ο γονότυπος τύπου 1 και το υψηλό ιϊκό φορτίο έναρξης είναι οι κύριοι ιϊκοί παράγοντες που σχετίζονται με χαμηλότερη ιολογική απάντηση στη θεραπεία ,ενώ για τον ασθενή οι παράγοντες που σχετίζονται με χαμηλότερη ιολογική απάντηση στη θεραπεία είναι η μη ανταπόκριση ή η υποτροπή σε προηγούμενη θεραπεία ,η παρουσία κίρρωσης ,η Αφροαμερικανική καταγωγή, η μεγαλύτερη των 40 ετών ηλικία, η μη συμμόρφωση στη θεραπεία και η παχυσαρκία. Τα οβάλ ηπατοκύτταρα είναι πρόδρομα ηπατικά κύτταρα που έχουν συσχετισθεί με την εξέλιξη της ηπατικής νόσου και την ανάπτυξη ηπατοκυτταρικού καρκινώματος σε πειραματικά μοντέλα .Πρόσφατα έχουμε αποδείξει ότι σε περιπτώσεις χρόνιας ηπατίτιδας τύπου Β ή C η παρουσία πρόδρομων ηπατικών κυττάρων σχετίζεται με τη σοβαρότητα της νόσου το βαθμό ίνωσης και το σχετιζόμενο κίνδυνο ανάπτυξης ηπατοκυτταρικού καρκινώματος Αυτή η μελέτη προσπάθησε να εντοπίσει τους παράγοντες που παίζουν καθοριστικό ρόλο στην μακροχρόνια ανταπόκριση στη θεραπεία ασθενών με χρόνια ηπατίτιδα C καθώς και τον ρόλο που μπορεί να έχει σε αυτή τη διαδικασία η ύπαρξη πρόγονων ηπατικών κυττάρων . Στόχος του έργου είναι η διερεύνηση ποικίλων κλινικών γενετικών εργαστηριακών και ιστολογικών παραμέτρων οι οποίες σχετίζονται με τη θεραπεία σε ασθενείς με χρόνια HCV λοίμωξη. Δευτερογενής στόχος της μελέτης είναι ο καθορισμός ομάδων υψηλού κινδύνου για την ανάπτυξη κίρρωσης και ηπατοκυτταρικού καρκίνου. ΣΧΕΔΙΑΣΜΟΣ 135 ενήλικες ασθενείς με θετική PCR και με βιοψία ήπατος που πιστοποιούσε χρόνια ηπατίτιδα εισήχθησαν στη μελέτη και τυχαιοποιήθηκαν να λάβουν είτε μονοθεραπεία με 3 MU ιντερφερόνης a2b τρεις φορές την εβδομάδα για 24 εβδομάδες ή συνδιασμό με ιντερφερόνη ή ή πεγκυλιωμένη ιντερφερόνη a2a (40 KD) μία φορά την εβδομάδα και προσθήκη 1000ή1200 mg ριμπαβιρίνης για 24 ή 48 εβδομάδες ανάλογα τον γονότυπο .Όλοι οι ασθενείς παρακολουθούνταν για την ασφάλεια την αντοχή και την αποτελεσματικότητα στο τέλος της εβδομάδας 2, 4, 8 και κάθε 4 εβδομάδες κατά τη διάρκεια της θεραπείας . Μετά την ολοκλήρωση της θεραπείας οι ασθενείς παρακολουθούνταν στις εβδομάδες 4, 12, 24 . Το πρώιμο τελικό σημείο ήταν η απώλεια του μετρήσιμου RNA του ιού της ηπατίτιδας C (HCV- RNA < 100c/ml) την εβδομάδα 24 μετά το τέλος της θεραπείας . Για να μελετήσουμε τη συσχέτιση των πρόγονων ηπατικών κυττάρων με την ανταπόκριση στη θεραπεία μελετήθηκαν 77 ηπατικές βιοψίες από ισάριθμους ασθενείς με χρόνια ηπατίτιδα C. Σαν μάρτυρες χρησιμοποιήθηκαν 10 φυσιολογικές ηπατικές βιοψίες .29 ασθενείς που ανταποκρίθηκαν στη θεραπεία και είχαν αρνητική PCR στο τέλος της προκαθορισμένης περιόδου αποτέλεσαν την ομάδα (Α) .29 ασθενείς που δεν ανταποκρίθηκαν στη θεραπεία και είχαν θετική PCR στο τέλος της προκαθορισμένης περιόδου αποτέλεσαν την ομάδα (Β) και τέλος 19 ασθενείς που υποτροπίασαν μετά αρχική ανταπόκριση στη θεραπεία αποτέλεσαν την ομάδα (Γ).Εξετάσθηκαν τομές παραφίνης πάχους 4 μm και καταμετρήθηκαν τα κύτταρα με μορφολογία οβάλ ηπατοκυττάρων δηλαδή AFPmRNA(+) και πρωτεΐνες CK19 (+) CK7(+) LCA(-) KAI CD34(-) Τα αποτελέσματα εκφράστηκαν σε ποσοστό επί τις %για τα κύτταρα με τα αντίστοιχα μορφολογικά χαρακτηριστικά και συσχετίστηκαν με τις αντίστοιχες κλινικές παραμέτρους. Ηπατικά προγονικά κύτταρα παρουσιάστηκαν και στις 87 βιοψίες αν και ήταν σημαντικά λιγότερα στις βιοψίες ελέγχου. Σύμφωνα με την έκφραση AFPmRNA η επί της % έκφραση ήταν :Ομάδα Β 53.4+ 1.3 > Ομάδα Γ 49+1.8 > Ομάδα Α 30.7 + 1.9 Οι ασθενείς που έλαβαν ιντερφερόνη ανταποκρίθηκαν καλύτερα στη θεραπεία αν ήταν < 40 είχαν γονότυπος 3,ιστορικό IV Χρήσης ουσιών αρνητική PCR-HCV (-) στην εβδομάδα 24 μετά θεραπεία &είχαν απουσία κίρρωσης ενώ είχαν μικρότερη πιθανότητα ανταπόκρισης αν είχαν ηλικία >40 έτη γονότυπο 1 ιστορικό μετάγγισης, αυξημένη ALT ή παρουσία κίρρωσης. Οι ασθενείς που έλαβαν θεραπεία συνδιασμού είχαν ευνοϊκή πρόγνωση αν εμφάνιζαν γονότυπο 2 ή 3 και μη ευνοϊκή αν είχαν γονότυπο 1,4 παρουσία κίρρωσης& αυξημένη γGt . Οι αυξημένες τρανσαμινάσες δεν αποτελούσαν προγνωστικό δείκτη. Στους ασθενείς που έλαβαν θεραπεία με πεγκυλιωμενη ιντερφερονη η ηλικία ή η απουσία κίρρωσης δεν αποτελούσε ανεξάρτητο προγνωστικό παράγοντα αντίθετα με την παραμονή αυξημένης ALT & γGt στον 6ο μήνα θεραπείας Ανεξάρτητοι προγνωστικοί παράγοντες για οποιαδήποτε θεραπευτικό σχήμα ήταν η Ηλικία (< 40 ετών )και η απουσία κίρρωσης .Οι ασθενείς με Φυσιολογικές τρανσαμινάσες αποτελούσαν το 40% των ασθενών μας στη δική μας μελέτη φάνηκε ότι ανταποκρίνονται καλύτερα στη θεραπεία και Σε μικρότερο ποσοστό εμφανίζουν κίρρωση ( 7% ) ενώ οι ασθενείς με κίρρωση Ανταποκρίνονται λιγότερο καλά σε όλες τις θεραπείες εμφανίζουν μεγαλύτερη διάρκεια λοίμωξης,λιπώδες ήπαρ σε μεγαλύτερο ποσοστό (64%) Έχουν αυξημένα ποσοστά ALT-γGt. Ενώ η παρουσία κίρρωσης είναι ανεξάρτητη από τον γονότυπο Τα ΠΗΚ υπάρχουν συχνά σε βιοψίες ήπατος ασθενών με ΧΗC και εκφράζουν AFPmRNA Υπάρχει σημαντική συσχέτιση με τη σοβαρότητα της νόσου και την ανταπόκριση στη θεραπεία Τα ΠΗΚ μπορεί να αποτελέσουν ανεξάρτητο προγνωστικό παράγοντα για την ανταπόκριση στη θεραπεία σε ασθενείς με χρόνια ηπατίτιδα C. / The treatment of chronic hepatitis C remains a challenge, particularly for certain patients as several virus related and patient related factors are associated with a lower virologic response to therapy. Hepatitis C virus genotype 1and a high baseline viral load are the major viral factors associated with a lower virologic response to therapy .Patient –related factors include previous relapse or non response to treatment, the presence of cirrhosis, the African America ethnicity, older age, contraindications to treatment and obesity. Oval hepatocytes (HK) are liver stem cells which are involved in the progress of liver disease and hepatocellular carcinoma development in experimental models. We have previously shown that in case of chronic hepatitis type B or C the presence of OH is related to the severity of the disease, the grade of fibrosis and the relative risk for HCG development. This study try to determine the factors effect the long term suppression of hepatitis C virus and also investigate the correlation of OH expression with treatment response in patients with chronic hepatitis C. Design 135 patients aged 18 years or more with positive HCV RNA and liver biopsy, were enrolled and randomly allocated to one of three regimens: 3mega units (MU) interferon a2btree times a week for 24 weeks, 3mega units (MU) interferon a2b tree times a week, plus 1000-12000 mg ribavirine per day for 24 weeks or 48 weeks or peg interferon alfa-2a (40KD) plus ribavirine 1000 or 1200 per day for 24 or 48 weeks because of different genotype. All patients were assessed for safety, tolerance and efficacy and the end of weeks 2, 4, 8and every 4 weeks during treatment. After treatment was completed patients were followed up on weeks 4, 12 and 24.The primary endpoint was loss of detectable HCV-RNA (serum HCV-RNA <100 copies/ml) at week 24 after treatment. The study comprised 77 liver biopsies obtained to an equal number of patients with chronic hepatitis C virus infection. To investigate the correlation of OH expression with treatment response ten normal liver biopsy were used as control. Twenty nine patients were assigned as responders (group A) 29 as non responders (group B) and 19 as releasers (group C). Paraffin sections (4μm thick) were subjected. To OH expretion . Cells with morphologic features of OH that were AFPmRNA or protein +/CK19+/CK7+ and LCA (-) /CD 34(-) were scored. Results were expressed as% of positive cells following morphometric analysis and correlated with the clinical parameters. Findings Sustained virological response at 24 weeks after treatment was found in 18( 22% ) of the 88 patient treated for 24 weeks with 3mega units (MU) interferon a2b three times a week ,35 ( 47%) of the 74 patient treated with the combination regiment, and 28 (60% ) of the 47 treated with peg interferon alfa-2a (40KD) plus ribavirine. Logistic recreation identified five independent factors significantly associated with response to treatment with interferon: genotype 2 or 3 , age forty years or less, minimal fibrosis stage, Ivd users , PCR negative at 6 months. Tree factors associated with the response to combination therapy: genotype 2 or 3, no cirrhosis, and high γgt the only factors significantly associated with response with the pegylated interferon treatment is high levels of γgt and alt to the sixth month of treatment. Oval hepatocyte expression was present in all 87 specimens, being significantly lower in controls compared with cases of chronic hepatitis C. According to the AFPmRNA expression, the grade for % OH expression was: (group B) non responders: 53.4+- 1.3> (Group C ) relapses :49+_1.8>(group A) responders30.7 +_1.9The difference was recorded as follows>(group A) vs. Bp<0.01, group A vs. C p<0.01, group B vs. C p<0.05. Conclusions This study demonstrates that OH are frequently present and expresses AFPmRNA in liver biopsies of patients with chronic hepatitis C. There is a significant association with the severity of disease and with response to treatment and may provide additional prognostic information and predict prognosis in cases of chronic hepatitis c. Age forty years or less and the presence of cirrhosis or no, they are independent factors significantly associated with response to any treatment. Patient with persistently normal or almost normal transaminase levels have higher virological response to therapy and less frequently cirrhosis Patient with cirrhosis exhibit lower response rates to therapy. The presents of cirrhosis is not related to genotype . Patients have frequently high levels of alt and γgt before and six months after therapy and have a worse virological response to any therapy.

Introduction: Breast cancer still remains the most common malignancy in women and its incidence is slowly increasing. A marked reduction of mortality has been achieved in the last 10 years thanks to modern diagnostic methods, mammary screening, and comprehensive and targeted cancer therapy. Modern diagnostic capabilities not only allow early diagnosis of a primary tumor lesion and precise determination of its biological nature before commencing treatment, but they also enable early diagnosis of local and regional recidives, including diagnosis of metastases in distant organs. In addition to clinical examination, conventional and complementary imaging examinations and tumor markers our objective was to determine the importance and use of growth factors in relation to the overall prognosis. The growth factors physiologically act already during the ontogenetic period when they control cell growth, proliferation, differentiation and apoptotic processes. It is known that they take part in the tumor growth processes which are characterized by autonomous behavior, increased proliferative activity, distinct differentiation activity and reduced apoptosis. Growth factors work as autoregulation factors in the neoplastic process as well as through their paracrine effects mediated by more or less specific receptors....

O interesse pela associação entre os hábitos alimentares e os fatores de crescimento e o câncer de mama foi recentemente elucidado. O risco e prognóstico do câncer de mama estar associado à composição corporal, fatores dietéticos, glicemia, fator de crescimento semelhante à insulina 1 e fator de crescimento vascular endotelial. Nosso objetivo foi identificar se o consumo de carnes vermelhas, leite de vaca e derivados, cereais integrais e refinados, linhaça, soja, chá verde, vegetais e frutas e os níveis séricos de glicose, IGF-1 e VEGF apresentam associação com os fatores prognósticos clínicos e patológicos do câncer de mama. Pacientes com câncer de mama submetidas à quimioterapia responderam a um questionário de freqüência alimentar semiquantitativo, e foram coletados dados antropométricos e sobre o estilo de vida. Amostras de sangue para dosagem de VEGF, IGF-1 e glicose foram coletadas antes do início da administração da quimioterapia. Os fatores prognósticos e dados da patologia foram coletados a partir dos prontuários. 61 pacientes entraram no estudo Foram analisados os dados de 59 pacientes. Houve associação entre glicemia de jejum e a circunferência da cintura (CC) (r2 = 0,16; β = 1,2; IC 95% 0,3-1,2; p = 0,002) e índice de massa corporal (r2 = 0,12; β = 1,295; IC 95% 0,4-2,1; p = 0,005), bem como entre glicemia de jejum e relação cintura-quadril(RCQ) (r2 = 0,07; β = 0,001; IC 95% 0-0,02; p = 0,04). Houve associação do maior tamanho do tumor e maior CC com a ingestão de mais de 226,1g de cereais refinados por dia (p <0,05). Houve associação do maior IMC, RCQ e CC com a ingestão de mais de 140,1 g de carne vermelha por dia (p <0,05).Nós encontramos resultados interessantes relacionados com a composição corporal e os níveis de glicemia de jejum e também com a composição corporal e ingestão de maiores quantidades de carne vermelha. Tumores de maior tamanho e maior CC foram relacionados à ingestão de cereais refinados, chamando a atenção para a necessidade de mais estudos avaliando o consumo deste grupo de alimentos em pacientes com câncer de mama. / Interest in the association of food habits, serum growth factors and breast cancer has been recently raised. Breast cancer risk and prognosis seems to be linked to body composition, dietary factors, serum glucose, insulin-like growth factor 1 and vascular endothelium growth factor. We aimed to identify whether the consumption of red meat, dairy products, whole and refined grains, fruits and vegetables and the levels of blood glucose, IGF-1 and VEGF were associated with prognostic factors in patients with breast cancer. Patients with breast cancer submitted to chemotherapy completed a semiquantitative foodfrequency questionnaire, and anthropometric and lifestyle data were collected. VEGF, IGF-1 and blood glucose were collected before chemotherapy administration. Breast cancer prognostic factors were collected from the pathology archives. 61 patients entered the study. Data were available for 59 patients. There was association between fasting glucose and waist circumference (WC) (r2=0.16; β=1.2; 95%CI 0.3-1.2; p=0.002) and body mass index (r2=0.12; β=1.295; 95%CI 0.4-2.1; p=0.005) as well as between fasting glucose and waist-to-hip ratio (r2=0.07; β=0.001; 95%CI 0-0.02; p=0.04). There was association of larger tumor size and larger WC with the ingestion of more than 226.1 g of processed refined grains per day (p<0.05). There was association of larger BMI, WHR and WC with the ingestion of more than 140.1 g of red meat per day (p<0.05). We have found interesting findings related to body composition and fasting glucose levels as well as body composition and ingestion of higher amounts of red meat. Larger tumor size and larger WC were related to the ingestion of processed refined grains, drawing attention to the need of further studies evaluating this food group in patients with breast cancer.

O presente estudo compreende 96 transplantes de medula óssea (TMO) de doadores HLA-idênticos em pacientes portadores de Leucemia Mielóide Crônica, no período de Junho de 1986 a Junho de 1998. A autora selecionou diversas covariáveis para serem estudadas como fatores prognósticos de cinco desfechos principais: ocorrência de doença enxerto contra hospedeiro (DECH) aguda e crônica, incidência de recaída, sobrevida livre de doença (SLD) e sobrevida global (SG). As covariáveis estudadas foram: idade, sexo, escolaridade, tempo entre o diagnóstico e o transplante, fase da doença ao transplante, regime de condicionamente, profilaxia de DECH, compatibilidade de sexo entre doador e receptor, sexo do doador, tamanho do baço e do fígado, percentagem de blastos e número de plaquetas no sangue periférico na primeira consulta ao CEMO, ocorrência e grau de DECH aguda, ocorrência de DECH crônica e tempo para recuperação de plaquetas após o TMO. Não foi encontrada associação estatisticamente significativa num nível de 95% de confiança entre qualquer das covariáveis e a ocorrência de DECH crônica ou de recaída. A ocorrência de DECH aguda mostrou-se associada apenas com a fase da doença ao transplante. As covariáveis que se mostraram associadas com a sobrevida global e a sobrevida livre de doença foram: a percentagem de blastos no sangue periférico e tamanho do baço na primeira consulta ao CEMO, a fase da doença ao transplante, o tipo de profilaxia de DECH, a ocorrência e o grau de DECH aguda e o tempo para recuperação de plaquetas num nível acima de 20 x 103/mm3. / This study comprises 96 bone marrow transplantations (BMT) from HLA-identical siblings in patients with Chronic Myeloid Leukaemia (CML), from June 1986 to June 1998. The author selected several covariates to be studied as prognostic factors for five main endpoints: acute and chronic graft versus host disease (GVHD) occurrence, relapse incidence (RI), disease free survival (DFS) and overall survival (OS). The covariates studied were: age, sex, years of schooling, time from diagnosis to transplantation, disease phase at BMT, conditioning regimen, GVHD prophylaxis, sexmatch between donor-receptor, donor sex, spleen and liver size, blasts percentage and platelet counts in peripheral blood at first consultation at CEMO, acute GVHD occurrence and grade, chronic GVHD occurrence and time to platelet recovery after BMT. No statistically significant association was found between the covariates studied and the occurrence of acute or chronic GVHD or of relapse. The covariates found to have an association with overall survival (OS) and disease free survival (DFS) were the percentage of blasts in peripheral blood and the spleen size at first consultation, the disease phase at transplant, type of GVHD prophylaxis, the occurrence and grade of acute GVHD and the time to platelet recovery above 20 x 103/mm3.

A hepatite C é uma doença recentemente reconhecida cujo tratamento é de eficácia aquém da desejável. O objetivo deste estudo é conhecer os fatores prognósticos de resposta virológica sustentada (RVS) e de efetividade do tratamento da hepatite C crônica e propor um modelo teórico que contenha as principais relações identificadas. A prevalência do HCV no Brasil é estimada entre 0,94% a 1,89%, com tendência a aumentar. Há populações especificamente sob maior risco como detentos, usuários de drogas e renais crônicos em diálise. Devido ao seu caráter crônico e progressivo estima-se que as complicações relacionadas aumentem nas próximas décadas caso não haja tratamento efetivo. O tratamento é caro, com efeitos colaterais importantes e promove RVS apenas em uma parcela dos indivíduos, mesmo sob condições ideais. São descritos como fatores prognósticos para RVS: genótipo, carga viral pré-tratamento, cinética viral, transaminases, estágio de fibrose, sexo, idade, peso, raça, esteatose e aderência ao tratamento. Dispensado de acordo com critérios do Ministério da Saúde, o tratamento utiliza interferon peguilado para o genótipo 1 e interferon convencional para os genótipos 2 e 3, associado à ribavirina. Associados a RVS, além do custo, outros fatores concorrem para a efetividade do tratamento: diagnóstico precoce dos casos, implementação de pólos de aplicação, qualidade e disponibilidade da medicação, critérios e interrupção precoce através da cinética viral, redução da necessidade de re-tratamento e de transplante hepático. Para aumentar a efetividade do tratamento concluímos ser necessário melhor rastreamento dos casos de infecção pelo VHC, disseminação de pólos de aplicação dos medicamentos e viabilizar exames para cinética viral. / Chronic C hepatitis is a recently recognized entity which treatment efficacy is not definitely established. The aim of this study is to know the prognostic factors for sustained virologic response and effectiveness of the treatment, as well as propose a theoretical model concerning its main issues. Brazilian prevalence of hepatitis C is around 0,94% to 1,89%, with an increasing tendency. Prisoners, drug addicts and patients in dialysis are at greater risk of infection. Related complications tend to increase in the next decades due to the chronic and progressive diseases character. Only part of treated patients obtain virologic sustained response even in optimal conditions. VHC genotype, pretreatment viral load, viral kinetic, aminotransferases levels, fibrosis, gender, age, body weight, race, steatosis and treatment adherence are prognostic factors associated with a sustained virologic response. According to the Brazilian control strategy peguilated interferon is used for treatment of genotype 1 and conventional interferon for genotypes 2 and 3. Other factors act along virologic sustained response for treatment effectiveness, such as related costs, early diagnosis, quality and availability of medication, pólos de aplicação, early stop criteria implementation, reduced number of retreatments and liver transplantations. In conclusion, to improve hepatitis C treatment effectiveness is necessary to optimize screening programs, implement more pólos de aplicação and make viral kinetic viable.

CXCR4, récepteur de la chimiokine SDF-1 (stromal cell-derived factor 1) joue un rôle capital dans l’hématopoïèse normale mais aussi dans la biologie de la cellule leucémique. Ce récepteur est exprimé à la surface des blastes et participe à « l’ancrage » de la cellule souche leucémique (CSL) au sein de la niche médullaire. Les interactions de la CSL avec le micro-environnement sont source de signaux de survie et de résistance à l’apoptose. La première partie de ce travail correspond à deux analyses en cytométrie en flux de l’expression de CXCR4 et de molécules d’adhérence sur des échantillons diagnostiques de LAM (leucémie aiguë myéloïde). Ce travail confirme la valeur pronostique péjorative de l’expression de CXCR4 et propose un modèle de stratification pronostique des patients, en fonction de leur phénotype d’adhérence. La deuxième partie s’intéresse à l’identification de potentielles cibles thérapeutiques dans un modèle de LAL à chromosome Philadelphie, pathologie au pronostic sombre malgré les progrès thérapeutiques liés aux ITK (inhibiteurs de tyrosine kinase). L’inhibition de CXCR4 par l’AMD3100 permet de potentialiser l’efficacité de l’aracytine et du dasatinib dans un modèle de co-culture stromale avec la lignée SUPB15. Une deuxième piste de ciblage thérapeutique de la LAL Phi+ est l’inhibition de la protéine chaperone HSP90. Une expression forte de HSP90 (dans les LAL Phi+ par rapport aux LAL Phi-) s’associe à une plus grande cytotoxicité du 17-AAG. En conclusion, CXCR4 est un récepteur clé de la cellule leucémique. L’étude de son niveau d’expression permet des stratifications pronostiques des patients et son blocage en fait une cible thérapeutique prometteuse / CXCR4, receptor of the chemokine SDF-1 (stromal cell-derived factor 1) plays a major role in the normal hematopoiesis but also in the biology of the leukaemic cell. This receptor is expressed on the surface of blasts and is a key molecule in "the anchoring" of the leukaemic stem cell (LSC) within the bone marrow niche. The interactions of the LSC with the bone marrow microenvironment promote survival signals and drug resistance. The first part of this work consists of two flow cytometry analyses of CXCR4 and adhesion molecules expression in patients with AML (acute myeloid leukaemia) at diagnosis. The results confirm that CXCR4 expression is associated with poor prognosis and this work proposes to stratify patients, according to their adhesive phenotype, in order to establish risk-adapted strategies. The second part deals with the identification of potential therapeutic targets in a model of ALL with chromosome Philadelphia. Despite therapeutic improvements with the ITK (tyrosine kinase inhibitors) era, long term survival remains poor. The inhibition of CXCR4 by the AMD3100 enhances the sensitivity of SUPB15 cell line to cytarabine and dasatinib therapy in a model of stromal co-culture. A second way of therapeutic targeting of the ALL Phi + is the inhibition of the heat-shock protein HSP90. High percentage of HSP90-positive cells (in Ph+ ALL samples) is associated with high sensitivity to 17-AAG. In conclusion, CXCR4 appears as a key receptor of the leukaemic cell. The analysis of its level of expression allows prognostic stratifications and its blockade represents a promising therapeutic target

O presente estudo compreende 96 transplantes de medula óssea (TMO) de doadores HLA-idênticos em pacientes portadores de Leucemia Mielóide Crônica, no período de Junho de 1986 a Junho de 1998. A autora selecionou diversas covariáveis para serem estudadas como fatores prognósticos de cinco desfechos principais: ocorrência de doença enxerto contra hospedeiro (DECH) aguda e crônica, incidência de recaída, sobrevida livre de doença (SLD) e sobrevida global (SG). As covariáveis estudadas foram: idade, sexo, escolaridade, tempo entre o diagnóstico e o transplante, fase da doença ao transplante, regime de condicionamente, profilaxia de DECH, compatibilidade de sexo entre doador e receptor, sexo do doador, tamanho do baço e do fígado, percentagem de blastos e número de plaquetas no sangue periférico na primeira consulta ao CEMO, ocorrência e grau de DECH aguda, ocorrência de DECH crônica e tempo para recuperação de plaquetas após o TMO. Não foi encontrada associação estatisticamente significativa num nível de 95% de confiança entre qualquer das covariáveis e a ocorrência de DECH crônica ou de recaída. A ocorrência de DECH aguda mostrou-se associada apenas com a fase da doença ao transplante. As covariáveis que se mostraram associadas com a sobrevida global e a sobrevida livre de doença foram: a percentagem de blastos no sangue periférico e tamanho do baço na primeira consulta ao CEMO, a fase da doença ao transplante, o tipo de profilaxia de DECH, a ocorrência e o grau de DECH aguda e o tempo para recuperação de plaquetas num nível acima de 20 x 103/mm3. / This study comprises 96 bone marrow transplantations (BMT) from HLA-identical siblings in patients with Chronic Myeloid Leukaemia (CML), from June 1986 to June 1998. The author selected several covariates to be studied as prognostic factors for five main endpoints: acute and chronic graft versus host disease (GVHD) occurrence, relapse incidence (RI), disease free survival (DFS) and overall survival (OS). The covariates studied were: age, sex, years of schooling, time from diagnosis to transplantation, disease phase at BMT, conditioning regimen, GVHD prophylaxis, sexmatch between donor-receptor, donor sex, spleen and liver size, blasts percentage and platelet counts in peripheral blood at first consultation at CEMO, acute GVHD occurrence and grade, chronic GVHD occurrence and time to platelet recovery after BMT. No statistically significant association was found between the covariates studied and the occurrence of acute or chronic GVHD or of relapse. The covariates found to have an association with overall survival (OS) and disease free survival (DFS) were the percentage of blasts in peripheral blood and the spleen size at first consultation, the disease phase at transplant, type of GVHD prophylaxis, the occurrence and grade of acute GVHD and the time to platelet recovery above 20 x 103/mm3.

A hepatite C é uma doença recentemente reconhecida cujo tratamento é de eficácia aquém da desejável. O objetivo deste estudo é conhecer os fatores prognósticos de resposta virológica sustentada (RVS) e de efetividade do tratamento da hepatite C crônica e propor um modelo teórico que contenha as principais relações identificadas. A prevalência do HCV no Brasil é estimada entre 0,94% a 1,89%, com tendência a aumentar. Há populações especificamente sob maior risco como detentos, usuários de drogas e renais crônicos em diálise. Devido ao seu caráter crônico e progressivo estima-se que as complicações relacionadas aumentem nas próximas décadas caso não haja tratamento efetivo. O tratamento é caro, com efeitos colaterais importantes e promove RVS apenas em uma parcela dos indivíduos, mesmo sob condições ideais. São descritos como fatores prognósticos para RVS: genótipo, carga viral pré-tratamento, cinética viral, transaminases, estágio de fibrose, sexo, idade, peso, raça, esteatose e aderência ao tratamento. Dispensado de acordo com critérios do Ministério da Saúde, o tratamento utiliza interferon peguilado para o genótipo 1 e interferon convencional para os genótipos 2 e 3, associado à ribavirina. Associados a RVS, além do custo, outros fatores concorrem para a efetividade do tratamento: diagnóstico precoce dos casos, implementação de pólos de aplicação, qualidade e disponibilidade da medicação, critérios e interrupção precoce através da cinética viral, redução da necessidade de re-tratamento e de transplante hepático. Para aumentar a efetividade do tratamento concluímos ser necessário melhor rastreamento dos casos de infecção pelo VHC, disseminação de pólos de aplicação dos medicamentos e viabilizar exames para cinética viral. / Chronic C hepatitis is a recently recognized entity which treatment efficacy is not definitely established. The aim of this study is to know the prognostic factors for sustained virologic response and effectiveness of the treatment, as well as propose a theoretical model concerning its main issues. Brazilian prevalence of hepatitis C is around 0,94% to 1,89%, with an increasing tendency. Prisoners, drug addicts and patients in dialysis are at greater risk of infection. Related complications tend to increase in the next decades due to the chronic and progressive diseases character. Only part of treated patients obtain virologic sustained response even in optimal conditions. VHC genotype, pretreatment viral load, viral kinetic, aminotransferases levels, fibrosis, gender, age, body weight, race, steatosis and treatment adherence are prognostic factors associated with a sustained virologic response. According to the Brazilian control strategy peguilated interferon is used for treatment of genotype 1 and conventional interferon for genotypes 2 and 3. Other factors act along virologic sustained response for treatment effectiveness, such as related costs, early diagnosis, quality and availability of medication, pólos de aplicação, early stop criteria implementation, reduced number of retreatments and liver transplantations. In conclusion, to improve hepatitis C treatment effectiveness is necessary to optimize screening programs, implement more pólos de aplicação and make viral kinetic viable.

O interesse pela associação entre os hábitos alimentares e os fatores de crescimento e o câncer de mama foi recentemente elucidado. O risco e prognóstico do câncer de mama estar associado à composição corporal, fatores dietéticos, glicemia, fator de crescimento semelhante à insulina 1 e fator de crescimento vascular endotelial. Nosso objetivo foi identificar se o consumo de carnes vermelhas, leite de vaca e derivados, cereais integrais e refinados, linhaça, soja, chá verde, vegetais e frutas e os níveis séricos de glicose, IGF-1 e VEGF apresentam associação com os fatores prognósticos clínicos e patológicos do câncer de mama. Pacientes com câncer de mama submetidas à quimioterapia responderam a um questionário de freqüência alimentar semiquantitativo, e foram coletados dados antropométricos e sobre o estilo de vida. Amostras de sangue para dosagem de VEGF, IGF-1 e glicose foram coletadas antes do início da administração da quimioterapia. Os fatores prognósticos e dados da patologia foram coletados a partir dos prontuários. 61 pacientes entraram no estudo Foram analisados os dados de 59 pacientes. Houve associação entre glicemia de jejum e a circunferência da cintura (CC) (r2 = 0,16; β = 1,2; IC 95% 0,3-1,2; p = 0,002) e índice de massa corporal (r2 = 0,12; β = 1,295; IC 95% 0,4-2,1; p = 0,005), bem como entre glicemia de jejum e relação cintura-quadril(RCQ) (r2 = 0,07; β = 0,001; IC 95% 0-0,02; p = 0,04). Houve associação do maior tamanho do tumor e maior CC com a ingestão de mais de 226,1g de cereais refinados por dia (p <0,05). Houve associação do maior IMC, RCQ e CC com a ingestão de mais de 140,1 g de carne vermelha por dia (p <0,05).Nós encontramos resultados interessantes relacionados com a composição corporal e os níveis de glicemia de jejum e também com a composição corporal e ingestão de maiores quantidades de carne vermelha. Tumores de maior tamanho e maior CC foram relacionados à ingestão de cereais refinados, chamando a atenção para a necessidade de mais estudos avaliando o consumo deste grupo de alimentos em pacientes com câncer de mama. / Interest in the association of food habits, serum growth factors and breast cancer has been recently raised. Breast cancer risk and prognosis seems to be linked to body composition, dietary factors, serum glucose, insulin-like growth factor 1 and vascular endothelium growth factor. We aimed to identify whether the consumption of red meat, dairy products, whole and refined grains, fruits and vegetables and the levels of blood glucose, IGF-1 and VEGF were associated with prognostic factors in patients with breast cancer. Patients with breast cancer submitted to chemotherapy completed a semiquantitative foodfrequency questionnaire, and anthropometric and lifestyle data were collected. VEGF, IGF-1 and blood glucose were collected before chemotherapy administration. Breast cancer prognostic factors were collected from the pathology archives. 61 patients entered the study. Data were available for 59 patients. There was association between fasting glucose and waist circumference (WC) (r2=0.16; β=1.2; 95%CI 0.3-1.2; p=0.002) and body mass index (r2=0.12; β=1.295; 95%CI 0.4-2.1; p=0.005) as well as between fasting glucose and waist-to-hip ratio (r2=0.07; β=0.001; 95%CI 0-0.02; p=0.04). There was association of larger tumor size and larger WC with the ingestion of more than 226.1 g of processed refined grains per day (p<0.05). There was association of larger BMI, WHR and WC with the ingestion of more than 140.1 g of red meat per day (p<0.05). We have found interesting findings related to body composition and fasting glucose levels as well as body composition and ingestion of higher amounts of red meat. Larger tumor size and larger WC were related to the ingestion of processed refined grains, drawing attention to the need of further studies evaluating this food group in patients with breast cancer.